The non-binding agreement combines AstraZeneca’s therapeutic knowledge with Oracle’s infrastructure to streamline the journey from drug discovery to patient treatment. Initial efforts will focus on oncology, rare diseases, and cardiovascular, renal, and metabolic conditions. By automating the identification of candidates, the firms hope to reduce the time patients spend waiting for access to experimental therapies.

Executives from both organizations, including AstraZeneca CEO Pascal Soriot and Oracle Health’s Seema Verma, emphasized that the initiative seeks to create a continuous learning model. This framework would allow insights generated during routine clinical care to inform future study designs and safety monitoring. By establishing shared governance and reusable technical components, the partners intend to test whether these digital workflows can be scaled across various geographies and complex disease landscapes.